title: [Novel anti-osteoporotic drugs on the horizon].
abstract: In recent years the great progress in knowledge on bone cell biology has allowed identification of molecular structures that can be targeted with pinpoint precision (druggable targets). Osteoclasts are regulated via the RANK-RANK-ligand (RANKL) signaling pathway and osteoblasts via the Wnt signaling pathway, both of which can be influenced for therapeutic measures. As a result the number of (functional) osteoclasts can be decreased or the genesis of osteoblasts can be increased and bone resorption is inhibited or bone formation is enhanced, respectively. Osteoclasts degrade collagen through cathepsin K and inactivation of this enzyme stabilizes the bone matrix; however, as osteoclasts are still able to maintain a stimulatory cross-talk with osteoblasts, formation of new bone will not be reduced. Parathyroid hormone-related protein plays a role in endochondral ossification and a synthetic analogue of this protein may have potent bone anabolic activity; however, the use of such new and highly efficient therapeutic principles comes with new questions and uncertainties on the sequence of therapies, duration of therapy, long-term side effects, undesired activation of metabolic pathways and effectiveness in comparison to other strategies of fracture prevention.
authors.affiliation: Zentrum für Innere Medizin, Abteilung für Gastroenterologie/Endokrinologie, Sektion Endokrinologie/Stoffwechselerkrankungen, Universitätsmedizin Rostock, E.-Heydemann-Str. 6, 18055, Rostock, Deutschland. andreas.knauerhase@uni-rostock.de.
authors.forename: A
authors.initials: A
authors.lastname: Knauerhase
authors.affiliation: Zentrum für Innere Medizin, Abteilung für Gastroenterologie/Endokrinologie, Sektion Endokrinologie/Stoffwechselerkrankungen, Universitätsmedizin Rostock, E.-Heydemann-Str. 6, 18055, Rostock, Deutschland.
authors.forename: H S
authors.initials: HS
authors.lastname: Willenberg
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D015195:Drug Design; D019317:Evidence-Based Medicine; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D010024:Osteoporosis / Q000188:drug therapy* / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D050071:Bone Density Conservation Agents
keywords: Abaloparatide; Cathepsin K; Odanacatib; Romosozumab; Wnt signaling pathway